Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.262
AS - Asia 6.394
EU - Europa 5.124
SA - Sud America 1.044
AF - Africa 180
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 26.028
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.738
SG - Singapore 2.258
CN - Cina 1.416
IT - Italia 1.259
HK - Hong Kong 959
BR - Brasile 787
RU - Federazione Russa 781
VN - Vietnam 680
SE - Svezia 525
UA - Ucraina 516
DE - Germania 502
IE - Irlanda 474
CA - Canada 424
GB - Regno Unito 270
FR - Francia 223
IN - India 214
BD - Bangladesh 195
FI - Finlandia 150
AT - Austria 135
AR - Argentina 106
KR - Corea 104
TR - Turchia 81
NL - Olanda 63
ZA - Sudafrica 63
IQ - Iraq 62
PK - Pakistan 61
ID - Indonesia 57
MX - Messico 56
JP - Giappone 53
DK - Danimarca 45
PH - Filippine 44
ES - Italia 40
PL - Polonia 39
EC - Ecuador 36
CO - Colombia 34
SA - Arabia Saudita 33
MA - Marocco 31
VE - Venezuela 25
UZ - Uzbekistan 24
BE - Belgio 23
JO - Giordania 17
KE - Kenya 17
MY - Malesia 17
PY - Paraguay 16
AE - Emirati Arabi Uniti 15
CH - Svizzera 14
IR - Iran 14
CL - Cile 13
TN - Tunisia 13
EG - Egitto 12
TH - Thailandia 12
UY - Uruguay 12
AU - Australia 11
RO - Romania 10
TW - Taiwan 10
ET - Etiopia 9
EU - Europa 9
IL - Israele 9
AL - Albania 8
CR - Costa Rica 8
JM - Giamaica 8
NP - Nepal 8
PE - Perù 8
SN - Senegal 8
BO - Bolivia 7
DZ - Algeria 7
LT - Lituania 7
PS - Palestinian Territory 7
DO - Repubblica Dominicana 6
HN - Honduras 6
AZ - Azerbaigian 5
LB - Libano 5
NI - Nicaragua 5
OM - Oman 5
PA - Panama 5
RS - Serbia 5
CZ - Repubblica Ceca 4
MN - Mongolia 4
AO - Angola 3
BG - Bulgaria 3
BY - Bielorussia 3
GR - Grecia 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
Totale 25.998
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.846
Singapore 1.254
Ashburn 1.188
Woodbridge 1.187
Hong Kong 935
Houston 681
Fairfield 677
San Jose 567
Jacksonville 524
Dublin 441
Chandler 414
Wilmington 401
Dearborn 335
Milan 317
New York 312
Seattle 301
Frankfurt am Main 297
Cambridge 255
Toronto 234
Santa Clara 228
Princeton 218
The Dalles 214
Chicago 209
Los Angeles 185
Ho Chi Minh City 183
Beijing 181
Dallas 160
Hanoi 156
Hefei 134
Vienna 122
Lauterbourg 109
Nanjing 109
Altamura 106
Lawrence 104
Rome 99
Shanghai 92
Lachine 91
Seoul 91
Boardman 80
Moscow 77
Council Bluffs 74
São Paulo 72
Buffalo 56
Fremont 49
Guangzhou 49
Andover 46
Helsinki 44
San Diego 44
Ottawa 41
London 39
Washington 39
Nanchang 38
Rio de Janeiro 37
Hebei 34
Munich 33
Orem 32
Changsha 31
Tianjin 30
Warsaw 30
Da Nang 29
Jakarta 29
Jiaxing 29
Shenyang 29
Tokyo 29
Atlanta 25
Baghdad 25
Johannesburg 25
Detroit 24
Brooklyn 23
Chennai 23
Salt Lake City 23
Brussels 22
Huizen 22
Kunming 22
Montreal 22
Nuremberg 22
Lahore 21
Pune 21
Tashkent 20
Falls Church 19
Norwalk 18
Phoenix 18
San Francisco 18
Ankara 17
Bologna 17
Denver 17
Hangzhou 17
Lissone 17
Manchester 17
Naples 17
Amsterdam 16
Amman 15
Belo Horizonte 15
Brasília 15
Haiphong 15
Dhaka 14
Dong Ket 14
Mexico City 14
Miami 14
Nairobi 14
Totale 16.755
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 580
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 542
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 437
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 419
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 400
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 387
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 383
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 366
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 364
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 345
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 344
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 319
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 317
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 305
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 303
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 302
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 293
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 279
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 275
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 274
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 272
Synchronous early-stage endometrial and ovarian cancer 271
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 269
Uterine leiomyosarcoma: analysis of treatment failures and survival 262
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 258
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 258
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 253
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 253
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 252
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 251
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 249
Fertility outcomes in stage I ovarian immature teratomas 246
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 245
Endometriomas: Their ultrasound characteristics 241
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 234
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 234
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 231
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 230
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 227
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 226
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 226
Endometrial stromal sarcoma: analysis of treatment failures and survival 226
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 226
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 224
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 224
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 222
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 222
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 221
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 219
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 219
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 219
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 218
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 215
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 215
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 212
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 211
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 209
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab 207
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 207
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 206
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 206
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 206
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 205
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 204
Optimal treatment of early-stage ovarian cancer 204
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 202
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 201
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 199
Antiemetic efficacy of granisetron in patients with gynecological malignancies 197
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 196
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 195
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 193
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 193
Color Doppler ultrasound in the preoperative assessment of adnexal masses 193
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 189
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 188
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 188
Tumor volume as risk factor for nodal diffusion in endometrial cancer 187
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 185
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 183
Ifosfamide in the treatment of malignant epithelial ovarian tumors 180
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 176
Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? 176
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 176
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 175
Clinically oriented three-step strategy for assessment of adnexal pathology 175
Brain metastases from endometrial carcinoma 173
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 170
Second-look laparotomy in the management of fallopian tube carcinoma 170
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 170
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 169
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: An Italian multicentric retrospective analysis 166
Fertility-sparing surgery in uterine leiomyosarcoma 164
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer 164
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 163
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial 158
Alpha-fetoprotein in the management of germ cell tumors of the ovary 158
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 154
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 151
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 151
Totale 23.797
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.665
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.665
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/20269.492 860 594 763 891 1.016 511 1.147 614 823 917 567 789
2026/2027233 233 0 0 0 0 0 0 0 0 0 0 0
Totale 26.435